ECM
ELDN icon

Element Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Element Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,376
Closed -$145K – 74
2017
Q2 		$145K Buy
+1,376
New +$140K 0.03% 115

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Element Capital Management's ELDN Position: Q3 2017 in Review

Element Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2017, closing a stake of 1,376 shares — an estimated $145K sold.

Element Capital Management first reported a position in ELDN in Q2 2017 and held it in 1 quarter. The position peaked at $145K in Q2 2017. 15 funds tracked by Wall St. Rank hold ELDN as of Q3 2017.

  • Element Capital Management reported no remaining Eledon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 1,376 Eledon Pharmaceuticals shares in Q3 2017, an estimated $145K.
  • Element Capital Management first reported a position in Eledon Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Eledon Pharmaceuticals position peaked at $145K in Q2 2017.
  • 15 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.